Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 1997

View Archived Issues

Glaxo Wellcome development pipeline

Taiho discloses anxiolytics

Agents for urinary incontinence from Nippon Shinyaku

Sigma-receptor antagonists disclosed by Taisho

Yamanouchi prepares hormonal agents for testosterone-dependent disorders

Somatostatin peptides prepared by Novartis

Novartis claims sLe(x)/sLe(a) mimetics

Antithrombotics from Fuji Yakuhin

MS&D describes nonpeptide tachykinin antagonists

Antiallergic compounds disclosed by Meiji Seika

Anti-HIV activity of herb used in traditional medicine

Abciximab and acute profound thrombocytopenia

ICAM-1 antisense oligonucleotide effective in murine model of colitis

GelTex Pharmaceuticals reports 1996 fourth-quarter and year-end results

Houghten Pharmaceuticals reports year-end and fourth-quarter 1996 results

Teva Pharmaceuticals reports financial results for 1996 fourth quarter and year end

1996, a milestone year for Theratechnologies

UroCor announces record fourth-quarter and year-end results

Genzyme Transgenics produces protential diabetes Rx in mouse milk

Neoprobe's peptides for surgical cancer detection covered by patent

Long-term clinical results reported for interferon gamma

DepoTech initiates pediatric clinical trial DepoCyt

New clinical results for Cypros' CPC-111

Amphotec now approved in 20 countries

NeoTherapeutics seeks approval for trials on neurological drug

Lilly and Emisphere sign agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...